Physician profile
Peter David Freeman
NPI 1467657510
$2,966.96
in general payments reported to CMS, 2019-2025
21 companies · $425 in 2025
The $425 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.75 · 2020: $83.55 · 2021: $216 · 2022: $179 · 2023: $347 · 2024: $1,687 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,561 · Travel and Lodging: $897.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,561.08 |
| Travel and Lodging | $897.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,154.06 | 2024 | Stellaris Elite, Teneo, Envista Aspire Iol |
| Genentech USA, INC. | $287.29 | 2022-2025 | Vabysmo, Susvimo, Lucentis |
| Alcon Vision LLC | $272.16 | 2022-2024 | Clareon |
| Rxsight INC | $160.60 | 2021-2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Apellis Pharmaceuticals, INC. | $143.66 | 2023-2025 | Syfovre |
| Tarsus Pharmaceuticals, INC. | $129.49 | 2024 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $128.18 | 2020-2022 | |
| Biotissue Holdings INC. | $123.93 | 2022-2025 | |
| Horizon Therapeutics Plc | $103.27 | 2023 | Tepezza |
| Allergan, INC. | $74.40 | 2020-2021 | |
| Abbvie INC. | $68.47 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $59.62 | 2019-2021 | |
| Amgen INC. | $51.77 | 2025 | Pavblu, Tepezza |
| Astellas Pharma US INC | $41.39 | 2025 | Izervay |
| Harrow Eye, LLC | $37.60 | 2025 | Vevye |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $26.71 | 2025 | Omidria |
| Oyster Point Pharma, INC. | $26.57 | 2023 | Tyrvaya |
| Sight Sciences, INC. | $25.43 | 2022 | |
| Dompe US, INC. | $19.61 | 2025 | Oxervate |
| Eyepoint US, INC. | $16.69 | 2020 | |
| Kala Pharmaceuticals, INC. | $16.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.